Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 12/20 | 0.54 |
| ▸ | GCG | P01275 | 8/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 1/20 | 0.46 |
| ▸ | GIPR | P48546 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654904 | 0.85 | GCG (0.56) | GCGRGCG | |
| SCHEMBL21544906 | 0.80 | GCGR (0.59) | GCGRGCGGLP1RGIPR | |
| SCHEMBL21562702 | 0.80 | GCGR (0.59) | GCGRGCGGLP1RGIPR | |
| SCHEMBL21544886 | 0.79 | GCGR (0.50) | GCGRGCGGLP1RGIPR | |
| SCHEMBL21544989 | 0.76 | GCGR (0.55) | GCGRGCGGLP1RGIPR | |
| SCHEMBL21544909 | 0.76 | GCGR (0.55) | GCGRGCGGLP1RGIPR | |
| SCHEMBL2653988 | 0.76 | GCG (0.46) | GCGRGCGEPHX2 | |
| SCHEMBL21562668 | 0.76 | GCGR (0.57) | GCGRGCG | |
| SCHEMBL21562783 | 0.76 | GCGR (0.57) | GCGRGCG | |
| SCHEMBL21562809 | 0.76 | GCGR (0.57) | GCGRGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951661-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | claimed |
| US-7696248-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | claimed |
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | claimed |
| EP-1951661-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007106181-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-09-20 | — | — | WO | claimed |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| EP-1951661-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1951661-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | disclosed |
| US-7696248-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696248-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | disclosed |
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | disclosed |
| EP-1951661-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007106181-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106181-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | GCGR 2/4885GCG 5/4885EPHX2 2409/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885GCG 5/4885EPHX2 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.